Searched for: subject:"Cholesterol"
(1 - 20 of 289)

Pages

document
Schlunk, F. (author), Fisher, P. (author), Princen, H.M.G. (author), Rex, A. (author), Prinz, V. (author), Foddis, M. (author), Lütjohann, D. (author), Laufs, U. (author), Endres, M. (author)
Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PSCK9) neutralizing antibodies effectively lower plasma cholesterol levels and decrease cardiovascular events but also raised some concern that cognitive function could worsen as a side effect. Here, we performed experiments in mice to characterize the effect of anti-PCSK9 antibodies...
article 2021
document
van Gemert, Y. (author), Kozijn, A.E. (author), Pouwer, M.G. (author), Kruisbergen, N.N.L. (author), van den Bosch, M.H.J. (author), Blom, A.B. (author), Pieterman, E.J. (author), Weinans, H. (author), Stoop, R. (author), Princen, H.M.G. (author), van Lent, P.L.E.M. (author)
Objective: High systemic cholesterol levels have been associated with osteoarthritis (OA) development. Therefore, cholesterol lowering by statins has been suggested as a potential treatment for OA. We investigated whether therapeutic high-intensive cholesterol-lowering attenuated OA development in dyslipidemic APOE*3Leiden.CETP mice. Methods:...
article 2021
document
Mueller, A.M. (author), Kleemann, R. (author), Gart, E. (author), van Duyvenvoorde, W. (author), Verschuren, L. (author), Caspers, M. (author), Menke, A. (author), Krömmelbein, N. (author), Salic, K. (author), Burmeister, Y. (author), Seilheimer, B. (author), Morrison, M.C. (author)
Background: Non-alcoholic fatty liver disease (NAFLD) is a complex multifactorial disorder that is characterised by dysfunctional lipid metabolism and cholesterol homeostasis, and a related chronic inflammatory response. NAFLD has become the most common cause of chronic liver disease in many countries, and its prevalence continues to rise in...
article 2021
document
Pouwer, M.G. (author)
The thesis discussed several strategies that may contribute to further CVD risk reduction in the future. We described two novel lipid-lowering strategies, we unraveled (part of) the etiology of the cardiovascular safety issues of TKIs that are used for the treatment of CML, and we investigated the dose effects of PFOA on lipoprotein metabolism....
doctoral thesis 2020
document
Schlunk, F. (author), Fisher, P. (author), Princen, H.M.G. (author), Rex, A. (author), Prinz, V. (author), Foddis, M. (author), Lütjohann, D. (author), Laufs, U. (author), Endres, M. (author)
Anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibodies lower low-density lipoprotein cholesterol levels and significantly reduce cardiovascular end points.1 Safety concerns were raised as ultra-low levels of low-density lipoprotein cholesterol can be achieved. Low cholesterol levels are associated with an increased rate of...
article 2020
document
Schuster, S. (author), Rubil, S. (author), Endres, M. (author), Princen, H.M.G. (author), Boeckel, J.N. (author), Winter, K. (author), Werner, C. (author), Laufs, U. (author)
LDL-cholesterol (LDL-C) is a causal pathogenic factor in atherosclerosis. Monoclonal anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) neutralizing antibodies are novel potent LDL-lowering drugs which reduce cardiovascular events. To characterize their effect on atherogenesis, APOE*3Leiden.CETP mice were fed a high cholesterol/high fat...
article 2019
document
Pouwer, M.G. (author), Pieterman, E.J. (author), Chang, S.C. (author), Olsen, G.W. (author), Verschuren, L. (author), Jukema, J.W. (author), Princen, H.M.G. (author)
Epidemiological studies have reported positive associations between serum perfluorooctanoic acid (PFOA) and total and non-high-density lipoprotein cholesterol (non-HDL-C) although the magnitude of effect of PFOA on cholesterol lacks consistency. The objectives of this study were to evaluate the effect of PFOA on plasma cholesterol and...
article 2019
document
Viester, L. (author), Verhagen, E.A.L.M. (author), Bongers, P.M. (author), van der Beek, A.J. (author)
Purpose: To evaluate the effectiveness of an individually tailored intervention for improvement in lifestyle behavior, health indicators, and prevention and reduction of overweight among construction workers. Design: Randomized controlled trial. Setting: Various blue-collar departments of a large construction company in the Netherlands....
article 2018
document
Fallaize, R. (author), Livingstone, K.M. (author), Celis-Morales, C. (author), Macready, A.L. (author), San-Cristobal, R. (author), Navas-Carretero, S. (author), Marsaux, C.F.M. (author), O’Donovan, C.B. (author), Kolossa, S. (author), Moschonis, G. (author), Walsh, M.C. (author), Gibney, E.R. (author), Brennan, L. (author), Bouwman, J. (author), Manios, Y. (author), Jarosz, M. (author), Martinez, J.A. (author), Daniel, H. (author), Saris, W.H.M. (author), Gundersen, T.E. (author), Drevon, C.A. (author), Gibney, M.J. (author), Mathers, J.C. (author), Lovegrove, J.A. (author)
Diet-quality scores (DQS), which are developed across the globe, are used to define adherence to specific eating patterns and have been associated with risk of coronary heart disease and type-II diabetes. We explored the association between five diet-quality scores (Healthy Eating Index, HEI; Alternate Healthy Eating Index, AHEI; MedDietScore,...
article 2018
document
San-Cristobal, R. (author), Navas-Carretero, S. (author), Livingstone, K.M. (author), Celis-Morales, C. (author), Macready, A.L. (author), Fallaize, R. (author), O’Donovan, C.B. (author), Lambrinou, C.P. (author), Moschonis, G. (author), Marsaux, C.F.M. (author), Manios, Y. (author), Jarosz, M. (author), Daniel, H. (author), Gibney, E.R. (author), Brennan, L. (author), Drevon, C.A. (author), Gundersen, T.E. (author), Gibney, M. (author), Saris, W.H.M. (author), Lovegrove, J.A. (author), Grimaldi, K. (author), Parnell, L.D. (author), Bouwman, J. (author), Ommen, B. (author), Mathers, J.C. (author), Alfredo Martinez, J. (author)
Mediterranean Diet (MedDiet) adherence has been proven to produce numerous health benefits. In addition, nutrigenetic studies have explained some individual variations in the response to specific dietary patterns. The present research aimed to explore associations and potential interactions between MedDiet adherence and genetic background...
article 2017
document
Hoeke, G. (author), Wang, Y. (author), van Dam, A.D. (author), Mol, M. (author), Gart, E. (author), Klop, H.G. (author), van den Berg, S.M. (author), Pieterman, E.H. (author), Princen, H.M.G. (author), Groen, A.K. (author), Rensen, P.C.N. (author), Berbée, J.F.P. (author), Boon, M.R. (author)
Background and aims Activation of brown adipose tissue (BAT) reduces both hyperlipidemia and atherosclerosis by increasing the uptake of triglyceride-derived fatty acids by BAT, accompanied by formation and clearance of lipoprotein remnants. We tested the hypothesis that the hepatic uptake of lipoprotein remnants generated by BAT activation...
article 2017
document
Simic, B. (author), Mocharla, P. (author), Crucet, M. (author), Osto, E. (author), Kratzer, A. (author), Stivala, S. (author), Kühnast, S. (author), Speet, T. (author), Doycheva, P. (author), Princen, H.M.G. (author), van der Hoorn, J.W.A. (author), Jukema, J.W. (author), Giral, H. (author), Tailleux, A. (author), Landmesser, U. (author), Syaels, B. (author), Lüscher, T.F. (author)
Background and aims. High-density lipoprotein cholesterol (HDL-C) is inversely related to cardiovascular risk. HDL-C raising ester transfer protein (CETP) inhibitors, are novel therapeutics. We studied the effects of CETP inhibitors anacetrapib and evacetrapib on triglycerides, cholesterol and lipoproteins, cholesterol efflux, paraoxonase...
article 2017
document
van den Broek, T.J. (author), Bakker, G.C.M. (author), Rubingh, C.M. (author), Bijlsma, S. (author), Stroeve, J.H.M. (author), van Ommen, B. (author), van Erk, M.J. (author), Wopereis, S. (author)
Background: A key feature of metabolic health is the ability to adapt upon dietary perturbations. A systemic review defined an optimal nutritional challenge test, the "PhenFlex test" (PFT). Recently, it has been shown that the PFT enables the quantification of all relevant metabolic processes involved in maintaining or regaining homeostasis of...
article 2017
document
Princen, H.M.G. (author), Pouwer, M.G. (author), Pieterman, E.J. (author)
article 2016
document
Stroeve, J.H.M. (author), Saccenti, E. (author), Bouwman, J. (author), Dane, A. (author), Strassburg, K. (author), Vervoort, J. (author), Hankemeier, T. (author), Astrup, A. (author), Smilde, A.K. (author), van Ommen, B. (author), Saris, W.H.M. (author)
Objective: Aim is to predict successful weight loss by metabolic signatures at baseline and to identify which differences in metabolic status may underlie variations in weight loss success. Methods: In DiOGenes, a randomized, controlled trial, weight loss was induced using a low calorie diet (800 kcal) for 8-weeks. Men (N5236) and women (N5431)...
article 2016
document
Broekhuizen, K. (author), van Wier, M.F. (author), Koppes, L.L.J. (author), Brug, J. (author), van Mechelen, W. (author), Bosmans, J.E. (author), Poppel, M.N. (author)
Background: Cost-effectiveness analyses provide insight in the use of lifestyle interventions. To evaluate the cost-effectiveness of a lifestyle intervention compared to usual care in people with Familial Hypercholesterolemia, 340 people with FH were randomized to the intervention or control group. LDL cholesterol, quality of life and costs were...
article 2015
document
Kühnast, S. (author), van der Tuin, S.J.L. (author), van der Hoorn, J.W.A. (author), van Klinken, J.B. (author), Simic, B. (author), Pieterman, E. (author), Havekes, L.M. (author), Landmesser, U. (author), Lüscher, T.F. (author), van Dijk, K.W. (author), Rensen, P.C.N. (author), Jukema, J.W. (author), Princen, H.M.G. (author)
Background The residual risk that remains after statin treatment supports the addition of other LDL-C-lowering agents and has stimulated the search for secondary treatment targets. Epidemiological studies propose HDL-C as a possible candidate. Cholesteryl ester transfer protein (CETP) transfers cholesteryl esters from atheroprotective HDL to...
article 2015
document
Liang, W. (author), Verschuren, L. (author), Mulder, P. (author), van der Hoorn, J.W.A. (author), Verheij, J. (author), van Dam, A.D. (author), Boon, M.R. (author), Princen, H.M.G. (author), Havekes, L.M. (author), Kleemann, R. (author), van den Hoek, A.M. (author)
BACKGROUND AND PURPOSE: Salsalate (salicylsalicylic acid) is an anti-inflammatory drug that was recently found to exert beneficial metabolic effects on glucose and lipid metabolism. Although its utility in the prevention and management of a wide range of vascular disorders, including type 2 diabetes and metabolic syndrome has been suggested...
article 2015
document
van der Tuin, S.J. (author), Kühnast, S. (author), Berbée, J. (author), Verschuren, L. (author), Pieterman, E.J. (author), Havekes, L.M. (author), van der Hoorn, J.W. (author), Rensen, P.C. (author), Jukema, J.W. (author), Princen, H.M. (author), Willems van Dijk, K. (author), Wang, Y. (author)
Recently, we showed in APOE*3-Leiden.CETP mice that anacetrapib attenuated atherosclerosis development by reducing (V)LDL-C rather than by raising HDL-C. Here, we investigated the mechanism by which anacetrapib reduces (V)LDL-C and whether this effect was dependent on the inhibition of CETP. APOE*3-Leiden.CETP mice were fed a Western type diet...
article 2015
document
Berbeé, J.F.P. (author), Boon, M.R. (author), Khedoe, P.P.S.J. (author), Bartelt, A. (author), Schlein, C. (author), Worthmann, A. (author), Kooijman, S. (author), Hoeke, G. (author), Mol, I.M. (author), John, C. (author), Jung, C. (author), Vazirpanah, N. (author), Brouwers, L.P.J. (author), Gordts, P.L.S.M. (author), Esko, J.D. (author), Hiemstra, P.S. (author), Havekes, L.M. (author), Scheja, L. (author), Heeren, J. (author), Rensen, P.C.N. (author)
Brown adipose tissue (BAT) combusts high amounts of fatty acids, thereby lowering plasma triglyceride levels and reducing obesity. However, the precise role of BAT in plasma cholesterol metabolism and atherosclerosis development remains unclear. Here we show that BAT activation by b3-adrenergic receptor stimulation protects from atherosclerosis...
article 2015
Searched for: subject:"Cholesterol"
(1 - 20 of 289)

Pages